PHARM-AD
PHARM-AD has been active since 2009 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €477k and a net result of €151k. Equity is growing by ~7% per year across the filed fiscal years. Its solvency ranks better than 70% of 7538 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
| Equity | €477k |
| Net result | €151k |
| Better than sector | 70% |
| Active | 16 yrs |
Exceptional profile, strong across almost every axis.
All 5 axes are computed from data Checked has read.
How do we compute this?
The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.
The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.
A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).
| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 72.3% | 50.9% | |
| Net result | €151k | €16k | |
| Equity | €477k | €58k | |
| Gross operating margin | €222k | €40k | |
| Total assets | €659k | €140k |
Figures by fiscal year and ratios
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Deposit | micro schema | micro schema | micro schema | micro schema |
| Revenue | - | - | - | - |
| EBITDA | €221k | €262k | €114k | €88k |
| Net profit | €151k | €179k | €80k | €57k |
| Cash flow | €151k | €180k | €82k | €67k |
| Staff costs | - | - | - | - |
| Income taxes | €68k | €81k | €32k | €22k |
| Dividends | €147k | €152k | - | - |
| Total assets | €659k | €733k | €491k | €396k |
| Equity | €477k | €473k | €446k | €366k |
| Debt | €183k | €260k | €45k | €30k |
| of which ≤ 1y | €183k | €254k | €42k | €25k |
| of which > 1y | - | - | - | - |
| Working capital | €464k | €475k | €448k | €368k |
| Employees (FTE) | - | - | - | - |
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Current ratio | 3.54 | 2.87 | 11.60 | 15.52 |
| Quick ratio | 3.54 | 2.87 | 11.60 | 15.52 |
| Working capital ratio | 70.4% | 64.8% | 91.3% | 93.0% |
| Solvency | 72.3% | 64.6% | 90.9% | 92.4% |
| Debt / equity | 0.38 | 0.55 | 0.10 | 0.08 |
| Long-term debt ratio | - | - | - | - |
| Interest coverage | 53.57 | 105.43 | 109.70 | 156.66 |
| Gross margin | - | - | - | - |
| Net margin | - | - | - | - |
| ROA | 22.8% | 24.5% | 16.4% | 14.5% |
| ROE | 31.6% | 37.9% | 18.0% | 15.7% |
| EBITDA margin | - | - | - | - |
| Days sales outstanding | - | - | - | - |
| Days payable outstanding | - | - | - | - |
| Inventory turnover | - | - | - | - |
| Days inventory (DSI) | - | - | - | - |
Full annual accounts (23 line items)
| Line item | Code | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Balance sheet, Assets | |||||
| TOTAL ASSETS | 20/58 | €659k | €733k | €491k | €396k |
| Fixed assets | 21/28 | €12k | €4k | €263 | €2k |
| Tangible fixed assets | 22/27 | €12k | €4k | €263 | €2k |
| Current assets | 29/58 | €647k | €729k | €490k | €394k |
| Amounts receivable within one year | 40/41 | €99k | €133k | €65k | €54k |
| Investments | 50/53 | €202k | €190k | €178k | €164k |
| Cash & bank | 54/58 | €344k | €406k | €247k | €174k |
| Balance sheet, Equity & liabilities | |||||
| TOTAL EQUITY & LIABILITIES | 10/49 | €659k | €733k | €491k | €396k |
| Equity | 10/15 | €477k | €473k | €446k | €366k |
| Contributions / capital | 10/11 | €6k | €6k | €6k | €6k |
| Reserves | 13 | €469k | €466k | €439k | €358k |
| Accumulated profits (losses) | 14 | €1k | €1k | €1k | €1k |
| Amounts payable | 17/49 | €183k | €260k | €45k | €30k |
| Amounts payable within one year | 42/48 | €183k | €254k | €42k | €25k |
| Trade debts payable within one year | 44 | €0 | €34k | €2k | €572 |
| Income statement | |||||
| Gross operating margin | 9900 | €222k | €263k | €114k | €89k |
| Operating result | 9901 | €220k | €262k | €112k | €79k |
| Financial income | 75 | €2k | €2k | €483 | €2k |
| Financial charges | 65 | €4k | €2k | €1k | €563 |
| Result before taxes | 9903 | €218k | €261k | €113k | €80k |
| Income taxes | 67/77 | €68k | €81k | €32k | €22k |
| Net result for the period | 9904 | €151k | €179k | €80k | €57k |
| Result to be appropriated | 9905 | €151k | €179k | €80k | €57k |
-
Current09-01-2024 → present
-
Current09-01-2024 → present
| NACE primary | Other business support services(82990) |
| Legal form | Private limited company(610) |
| Incorporation | 03-10-2009 |
| Status | Active |
| Postal code | 1370 |
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 25085D0247/00E000 | Wallonia | 939 m² | 1 · 150 m² | 9.8 m · 2 fl. |
We know of 3 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
13-05-2026 Notarial deed · General meeting · Statute amendment · First fiscal year
- Filing: 2026-05-11 · PHARM-AD
- Publication: 2026-05-13 · PHARM-AD
- Notarial deed: 2026-05-04 · PHARM-AD
- General meeting: date: 2026-05-04, type: extraordinaire · PHARM-AD
- Statute amendment: content: Modification de l'exercice social et de la date de l'assemblée générale ordinaire · PHARM-AD
- First fiscal year: end: 2026-12-31, start: 2026-01-01 · PHARM-AD
- Accounting effect: end: 2026-12-31, start: 2025-07-01 · PHARM-AD
- Annual meeting schedule: schedule: premier vendredi du mois de mai, à 17h00 au siège · PHARM-AD
- Power of attorney: date: 2026-05-04, purpose: faire le nécessaire auprès du guichet d’entreprise pour porter à leur connaissance et au notaire soussigné pour la coordination des statuts, granted_to: chacun des administrateurs · PHARM-AD
- Act object: ANNEE COMPTABLE, ASSEMBLEE GENERALE
Technical details
{
"facts": [
{
"type": "filing",
"quote": "D\u00E9pos\u00E9 11-05-2026",
"value": "2026-05-11",
"object": null,
"subject": "e1"
},
{
"type": "publication",
"quote": "Bijlagen bij het Belgisch Staatsblad - 13/05/2026 - Annexes du Moniteur belge",
"value": "2026-05-13",
"object": null,
"subject": "e1"
},
{
"type": "notarial_deed",
"quote": "Il r\u00E9sulte d\u2019un proc\u00E8s-verbal dress\u00E9 par le notaire Thibaut van DOORSLAER de ten RYEN, notaire associ\u00E9 \u00E0 Jodoigne, en date du 4 mai 2026",
"value": "2026-05-04",
"object": "e2",
"subject": "e1"
},
{
"type": "general_meeting",
"quote": "l\u0027assembl\u00E9e g\u00E9n\u00E9rale extraordinaire des actionnaires de la soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e \u00AB PHARM-AD\u00BB ... en date du 4 mai 2026",
"value": {
"date": "2026-05-04",
"type": "extraordinaire"
},
"object": null,
"subject": "e1"
},
{
"type": "statute_amendment",
"quote": "L\u2019assembl\u00E9e g\u00E9n\u00E9rale d\u00E9cide de remplacer \u2022 L\u2019article 17 premier alin\u00E9a par le texte suivant ... \u2022 l\u0027article 22 des statuts par le texte suivant",
"value": {
"content": "Modification de l\u0027exercice social et de la date de l\u0027assembl\u00E9e g\u00E9n\u00E9rale ordinaire",
"articles": [
"17",
"22"
]
},
"object": null,
"subject": "e1"
},
{
"type": "first_fiscal_year",
"quote": "L\u2019exercice social commence le 1er janvier et se termine le 31 d\u00E9cembre de chaque ann\u00E9e.",
"value": {
"end": "2026-12-31",
"start": "2026-01-01"
},
"object": null,
"subject": "e1"
},
{
"type": "accounting_effect",
"quote": "l\u2019exercice social en cours, ayant pris cours le 1er juillet 2025 se cl\u00F4turera le 31 d\u00E9cembre 2026.",
"value": {
"end": "2026-12-31",
"start": "2025-07-01"
},
"object": null,
"subject": "e1"
},
{
"type": "annual_meeting_schedule",
"quote": "La date de l\u2019assembl\u00E9e g\u00E9n\u00E9rale ordinaire est en cons\u00E9quence d\u00E9sormais fix\u00E9e au premier vendredi du mois de mai, \u00E0 17h00 au si\u00E8ge.",
"value": {
"schedule": "premier vendredi du mois de mai, \u00E0 17h00 au si\u00E8ge"
},
"object": null,
"subject": "e1"
},
{
"type": "power_of_attorney",
"quote": "L\u2019assembl\u00E9e donne tous pouvoirs \u00E0 chacun des administrateurs, avec facult\u00E9 de substitution, pour faire le n\u00E9cessaire aupr\u00E8s du guichet d\u2019entreprise pour porter \u00E0 leur connaissance et au notaire soussign\u00E9 pour la coordination des statuts.",
"value": {
"date": "2026-05-04",
"purpose": "faire le n\u00E9cessaire aupr\u00E8s du guichet d\u2019entreprise pour porter \u00E0 leur connaissance et au notaire soussign\u00E9 pour la coordination des statuts",
"granted_to": "chacun des administrateurs"
},
"object": null,
"subject": "e1"
},
{
"type": "act_object",
"quote": "Objet de l\u0027acte : ANNEE COMPTABLE, ASSEMBLEE GENERALE",
"value": "ANNEE COMPTABLE, ASSEMBLEE GENERALE",
"object": null,
"subject": null
}
],
"act_meta": {
"model_id": 40,
"extractor": "open-capture-27b-v3",
"ocr_chars": 3208,
"truncated": false,
"needs_verify": false
},
"entities": [
{
"id": "e1",
"kbo": "0819.236.165",
"kind": "company",
"name": "PHARM-AD",
"attrs": {
"seat": "Rue Sainte-Gertrude(Pi\u00E9t.) 5, 1370 Jodoigne-Souveraine",
"legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e"
}
},
{
"id": "e2",
"kbo": null,
"kind": "person",
"name": "Thibaut van DOORSLAER de ten RYEN",
"attrs": {
"role": "notaire"
}
}
]
}09-01-2024 Articles of association amended
Technical details
{
"schema": "v3.2",
"act_meta": {
"model_id": 36,
"extractor": "constrained-core-35b"
},
"statute_change": {
"name_change": false,
"seat_change": false,
"object_change": false,
"effective_date": "2024-01-04",
"legal_form_change": false
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "0819.236.165",
"name_full": "PHARM-AD",
"legal_form": "SPRL"
},
"signature_regime": "solo",
"special_mandates": [],
"governance_change": {
"admin_delegated_added": []
}
}| Legal nameFR | PHARM-AD |